SOUTH SAN FRANCISCO, Feb. 12, 2018 /PRNewswire/ -- GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, will be presenting the findings of its research on novel approaches to antibody development and T cell discovery for diseases of immune dysregulation at two upcoming Keystone Symposia conferences. The first conference, "Emerging Cellular Therapies: T Cells and Beyond," will take place Feb. 11-15 in Keystone, Colo., and the second, "Antibodies as Drugs: Translating Molecules into Treatments," will be held Feb. 25-March 1 in Whistler, British Columbia.
- Matthew Spindler, Ph.D., Director of T Cell Engineering at GigaGen, will present poster #3012, titled "Discovery of Potent Anti-Tumor TCRs in Recombinant TCR Libraries Generated from Tumor Infiltrating Lymphocytes," from 7:30-10 p.m. MST on Wednesday, Feb. 14, at Keystone Resort in Keystone, Colo.
- Adam Adler, Ph.D., Vice President of Research and Development at GigaGen, will present poster #1001, titled "Rapid Discovery of High-Affinity, Human Antibodies Against 17 Immuno-Oncology Targets Using Molecular Genomic Screening Methods," from 7:30-10 p.m. PST on Monday, Feb. 26, at the Whistler Conference Centre in Whistler, British Columbia.
The Keystone Symposia on Molecular and Cellular Biology is a nonprofit organization that convenes a series of peer-reviewed conferences throughout the year on a broad range of life science disciplines, with the goal of serving as a catalyst for biomedical advancement.
GigaGen is a privately-held, preclinical biopharmaceutical company developing novel antibody therapies to treat diseases of immune dysregulation. GigaGen's deep understanding of immune dysregulation is enabled by industry-leading technology that quickly captures the genetic makeup of entire immune repertoires to analyze B cells at a rate of millions per hour, while simultaneously identifying their antigen and protein binders. GigaGen has a robust internal pipeline consisting of novel antibodies against immuno-oncology targets, in addition to the first recombinant intravenous immunoglobulin (IVIG) for patients with immune deficiency. For more information visit www.GigaGen.com.
SOURCE GigaGen Inc.